-
Signature
-
/s/ John S. Hess, Jr. under Power of Attorney
-
Issuer symbol
-
UTHR
-
Transactions as of
-
02 Sep 2025
-
Net transactions value
-
-$872,730
-
Form type
-
4
-
Filing time
-
02 Sep 2025, 16:39:02 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| CAUSEY CHRISTOPHER |
Director |
C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING |
/s/ John S. Hess, Jr. under Power of Attorney |
02 Sep 2025 |
0001237334 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
UTHR |
Common Stock |
Options Exercise |
$396,900 |
+3,000 |
+62% |
$132.30 |
7,865 |
02 Sep 2025 |
Direct |
F1 |
| transaction |
UTHR |
Common Stock |
Sale |
$419,630 |
-1,000 |
-13% |
$419.63 |
6,865 |
02 Sep 2025 |
Direct |
F1 |
| transaction |
UTHR |
Common Stock |
Sale |
$430,000 |
-1,000 |
-15% |
$430.00 |
5,865 |
02 Sep 2025 |
Direct |
F1 |
| transaction |
UTHR |
Common Stock |
Sale |
$420,000 |
-1,000 |
-17% |
$420.00 |
4,865 |
02 Sep 2025 |
Direct |
F1 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
UTHR |
Stock Option |
Options Exercise |
$0 |
-3,000 |
-100% |
$0.000000 |
0 |
02 Sep 2025 |
Common Stock |
3,000 |
$132.30 |
Direct |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: